Rohit Bakshi

List of Publications by Citations

169 papers	8,574 citations	52 h-index	88 g-index
183 ext. papers	9,860 ext. citations	5.3 avg, IF	5.93 L-index

#	Paper	IF	Citations
169	Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. *Journal of the Neurological Sciences*, **2005**, 231, 29-34	3.2	378
168	The measurement and clinical relevance of brain atrophy in multiple sclerosis. *Lancet Neurology, The*, **2006**, 5, 158-70	24.1	341
167	Fatigue associated with multiple sclerosis: diagnosis, impact and management. *Multiple Sclerosis Journal*, **2003**, 9, 219-27	5	314
166	Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. *Archives of Neurology*, **2004**, 61, 226-30		304
165	Gray matter involvement in multiple sclerosis. *Neurology*, **2007**, 68, 634-42	6.5	280
164	Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. *Nature Medicine*, **2014**, 20, 1147-56	50.5	267
163	MRI in multiple sclerosis: current status and future prospects. *Lancet Neurology, The*, **2008**, 7, 615-25	24.1	262
162	Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. *Neurology*, **2006**, 66, 685-92	6.5	233
161	Iron in chronic brain disorders: imaging and neurotherapeutic implications. *Neurotherapeutics*, **2007**, 4, 371-86	6.4	228
160	T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. *Archives of Neurology*, **2002**, 59, 62-8		204
159	Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. *NeuroImage*, **2010**, 50, 446-55	7.9	203
158	Brain MRI lesions and atrophy are related to depression in multiple sclerosis. *NeuroReport*, **2000**, 11, 1153-8	1.7	175
157	Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. *Archives of Neurology*, **2001**, 58, 742-8		152
156	Smoking and disease progression in multiple sclerosis. *Archives of Neurology*, **2009**, 66, 858-64		142
155	The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. *NeuroImage*, **2005**, 26, 1068-77	7.9	142
154	Magnetic resonance imaging of iron deposition in neurological disorders. *Topics in Magnetic Resonance Imaging*, **2006**, 17, 31-40	2.3	138
153	Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. *NeuroImage*, **2004**, 22, 1732-43	7.9	134

152	Correlating Brain Atrophy With Cognitive Dysfunction, Mood Disturbances, and Personality Disorder in Multiple Sclerosis. *Journal of Neuroimaging*, **2004**, 14, 36S-45S	2.8	120
151	High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis **1998**, 8, 228-34		112
150	Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. *Journal of Neuroimaging*, **2009**, 19, 3-8	2.8	102
149	Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. *NeuroImage*, **2007**, 36, 1294-300	7.9	100
148	A semiautomated measure of whole-brain atrophy in multiple sclerosis. *Journal of the Neurological Sciences*, **2003**, 208, 57-65	3.2	97
147	Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. *Journal of the Neurological Sciences*, **2001**, 185, 19-26	3.2	97
146	Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. *Archives of Neurology*, **2000**, 57, 1485-91		96
145	T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. *Journal of Neuroimaging*, **2007**, 17 Suppl 1, 16S-21S	2.8	94
144	Brain CT and MRI Findings in 100 Consecutive Patients with Intracranial Tuberculoma. *Journal of Neuroimaging*, **2003**, 13, 240-247	2.8	94
143	Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings. *Epilepsia*, **1998**, 39, 295-9	6.4	91
142	Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. *Archives of Neurology*, **2005**, 62, 1371-6		83
141	Imaging of multiple sclerosis: role in neurotherapeutics. *NeuroRx*, **2005**, 2, 277-303		83
140	Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study. *NeuroReport*, **2003**, 14, 335-9	1.7	83
139	Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. *Journal of Neuroimaging*, **2011**, 21, e50-6	2.8	82
138	Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. *Journal of Neuroimaging*, **2005**, 15, 30S-45S	2.8	81
137	The association between cognitive impairment and quality of life in patients with early multiple sclerosis. *Journal of the Neurological Sciences*, **2010**, 290, 75-9	3.2	77
136	Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks. *NeuroImage*, **2019**, 184, 901-915	7.9	77
135	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study. *Journal of Neuroimaging*, **2003**, 13, 307-314	2.8	76

134	The relationships among MRI-defined spinal cord involvement, brain involvement, and disability in multiple sclerosis. *Journal of Neuroimaging*, **2012**, 22, 122-8	2.8	74
133	Exploration of machine learning techniques in predicting multiple sclerosis disease course. *PLoS ONE*, **2017**, 12, e0174866	3.7	71
132	MRI in multiple sclerosis: what's inside the toolbox?. *Neurotherapeutics*, **2007**, 4, 602-17	6.4	70
131	Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. *Journal of Neuroimaging*, **2001**, 11, 129-36	2.8	70
130	Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. *Journal of Neuropsychiatry and Clinical Neurosciences*, **2002**, 14, 44-51	2.7	70
129	Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis **2004**, 14, 36S-45S		70
128	Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1478-1491	5.3	69
127	Low testosterone is associated with disability in men with multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 1584-92	5	68
126	Role of MRI in multiple sclerosis I: inflammation and lesions. *Frontiers in Bioscience - Landmark*, **2004** , 9, 665-83	2.8	67
125	Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study. *Journal of the Neurological Sciences*, **2009**, 279, 99-105	3.2	65
124	Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis. *American Journal of Neuroradiology*, **2017**, 38, 1501-1509	4.4	62
123	Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. *American Journal of Neuroradiology*, **2011**, 32, 515-21	4.4	62
122	3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis. *NeuroImage*, **2009**, 46, 633-41	7.9	61
121	The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. *Journal of Neuroimaging*, **2012**, 22, 129-36	2.8	56
120	Central Nervous System Atrophy and Clinical Status in Multiple Sclerosis. *Journal of Neuroimaging*, **2004**, 14, 27S-35S	2.8	53
119	Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review. *JAMA Neurology*, **2017**, 74, 100-109	17.2	52
118	Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. *Multiple Sclerosis Journal*, **2010**, 16, 39-44	5	49
117	Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. *Archives of Neurology*, **2008**, 65, 1449-53		48

116	Spatial distribution of multiple sclerosis lesions in the cervical spinal cord. *Brain*, **2019**, 142, 633-646	11.2	47
115	T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. *Multiple Sclerosis Journal*, **2009**, 15, 678-86	5	47
114	Approaches to normalization of spinal cord volume: application to multiple sclerosis. *Journal of Neuroimaging*, **2012**, 22, e12-9	2.8	44
113	Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. *Journal of Neuroimaging*, **2001**, 11, 184-8	2.8	42
112	MRI in multiple sclerosis: a review of the current literature. *Current Opinion in Neurology*, **2012**, 25, 402-9	7.1	40
111	Rate of brain atrophy in benign vs early multiple sclerosis. *Archives of Neurology*, **2009**, 66, 234-7		39
110	Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. *American Journal of Neuroradiology*, **2004**, 25, 985-96	4.4	39
109	Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis. *Journal of Neuroimaging*, **2016**, 26, 62-7	2.8	38
108	Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. *JAMA Neurology*, **2017**, 74, 275-285	17.2	37
107	COVID-19 in teriflunomide-treated patients with multiple sclerosis. *Journal of Neurology*, **2020**, 267, 2790-2796	3.3	37
106	The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. *BMC Neurology*, **2019**, 19, 23	3.1	33
105	The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. *Neurology*, **2004**, 63, S3-11	6.5	33
104	Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. *Journal of Neuroimmunology*, **2008**, 205, 113-25	3.5	32
103	Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening. *Radiology*, **2007**, 244, 823-31	20.5	32
102	Thalamic Involvement in Multiple Sclerosis: A Diffusion-Weighted Magnetic Resonance Imaging Study **2003**, 13, 307		32
101	Magnetic Resonance Imaging in Multiple Sclerosis. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	30
100	Power estimation for non-standardized multisite studies. *NeuroImage*, **2016**, 134, 281-294	7.9	28
99	Brain CT and MRI Findings in 100 Consecutive Patients with Intracranial Tuberculoma **2003**, 13, 240		28

98	7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. *Multiple Sclerosis Journal*, **2020**, 26, 177-187	5	28
97	Gut Microbiome in Progressive Multiple Sclerosis. *Annals of Neurology*, **2021**, 89, 1195-1211	9.4	27
96	Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI. *Journal of Neuroimaging*, **2018**, 28, 36-47	2.8	27
95	Microstructural changes in the striatum and their impact on motor and neuropsychological performance in patients with multiple sclerosis. *PLoS ONE*, **2014**, 9, e101199	3.7	26
94	COVID-19 mRNA vaccination leading to CNS inflammation: a case series. *Journal of Neurology*, **2021**, 1	5.5	26
93	Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. *Journal of the Neurological Sciences*, **2009**, 284, 116-9	3.2	25
92	Neuroimaging of HIV and AIDS related illnesses: a review. *Frontiers in Bioscience - Landmark*, **2004**, 9, 632-46	2.8	25
91	Cerebral venous infarctions presenting as enhancing space-occupying lesions: MRI findings **1998**, 8, 210-5		25
90	Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS. *Neurology*, **2019**, 92, 519-533	6.5	25
89	Lifespan normative data on rates of brain volume changes. *Neurobiology of Aging*, **2019**, 81, 30-37	5.6	24
88	Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2016**, 3, e200	9.1	24
87	Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2017**, 4, e359	9.1	24
86	Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. *Journal of Neuroimaging*, **2017**, 27, 481-485	2.8	23
85	MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. *Journal of the Neurological Sciences*, **2014**, 346, 250-4	3.2	23
84	Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors. *Journal of Neuroimaging*, **2015**, 25, 191-199	2.8	21
83	Multiple sclerosis medical image analysis and information management. *Journal of Neuroimaging*, **2005**, 15, 103S-117S	2.8	21
82	Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. *Npj Digital Medicine*, **2019**, 2, 123	15.7	21
81	MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. *Journal of Neurology*, **2010**, 257, 63-71	5.5	20

80	Acute transverse myelitis after influenza vaccination: magnetic resonance imaging findings **1996**, 6, 248-50		20
79	Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. *Journal of Neurology*, **2015**, 262, 2425-32	5.5	19
78	Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. *NeuroImage: Clinical*, **2015**, 8, 606-10	5.3	19
77	Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T -weighted brain MRI acquisitions. *Magnetic Resonance in Medicine*, **2018**, 79, 1595-1601	4.4	19
76	Incorporating domain knowledge into the fuzzy connectedness framework: application to brain lesion volume estimation in multiple sclerosis. *IEEE Transactions on Medical Imaging*, **2007**, 26, 1670-80	11.7	19
75	Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability. *BMC Neurology*, **2017**, 17, 172	3.1	18
74	The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. *Neurology and Therapy*, **2016**, 5, 215-229	4.6	18
73	Corpus callosum atrophy correlates with gray matter atrophy in patients with multiple sclerosis. *Journal of Neuroimaging*, **2015**, 25, 62-7	2.8	18
72	An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. *NeuroReport*, **2014**, 25, 1156-61	1.7	18
71	Combination therapy for multiple sclerosis: the treatment strategy of the future?. *CNS Drugs*, **2004**, 18, 777-92	6.7	18
70	T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis. *BMC Neurology*, **2015**, 15, 124	3.1	17
69	Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability. *Brain*, **2020**, 143, 2089-2105	11.2	17
68	Magnetic resonance imaging advances in multiple sclerosis. *Journal of Neuroimaging*, **2005**, 15, 5S-9S	2.8	17
67	Detection of aryl hydrocarbon receptor agonists in human samples. *Scientific Reports*, **2018**, 8, 4970	4.9	16
66	Multiple Sclerosis Lesion Segmentation with Tiramisu and 2.5D Stacked Slices.. *Lecture Notes in Computer Science*, **2019**, 11766, 338-346	0.9	16
65	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2020**, 7, 945-955	5.3	15
64	An Automated Statistical Technique for Counting Distinct Multiple Sclerosis Lesions. *American Journal of Neuroradiology*, **2018**, 39, 626-633	4.4	15
63	Automatic spinal cord localization, robust to MRI contrasts using global curve optimization. *Medical Image Analysis*, **2018**, 44, 215-227	15.4	15

62	Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e587	9.1	15
61	Adrenocorticotropic hormone methylprednisolone added to interferon in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. *Therapeutic Advances in Neurological Disorders*, **2017**, 10, 3-17	6.6	14
60	Multisite reliability and repeatability of an advanced brain MRI protocol. *Journal of Magnetic Resonance Imaging*, **2019**, 50, 878-888	5.6	14
59	Neuroimaging Curriculum for Neurology Trainees: Report from the Neuroimaging Section of the AAN. *Journal of Neuroimaging*, **2003**, 13, 215-217	2.8	14
58	MRI detection of hypointense brain lesions in patients with multiple sclerosis: T1 spin-echo vs. gradient-echo. *European Journal of Radiology*, **2015**, 84, 1564-1568	4.7	13
57	A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. *Journal of the Neurological Sciences*, **2017**, 383, 221-229	3.2	13
56	The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis. *Journal of Neuroimaging*, **2017**, 27, 33-36	2.8	13
55	Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. *Journal of the Neurological Sciences*, **2012**, 315, 49-54	3.2	13
54	18F-PBR06 Versus 11C-PBR28 PET for Assessing White Matter Translocator Protein Binding in Multiple Sclerosis. *Clinical Nuclear Medicine*, **2018**, 43, e289-e295	1.7	13
53	The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2017**, 17, 47-53	4	12
52	One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1125-31	5.5	12
51	MRI phenotypes in MS: Longitudinal changes and miRNA signatures. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e530	9.1	11
50	The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. *Journal of Neuroimaging*, **2016**, 26, 184-7	2.8	11
49	Correlation between white matter damage and gray matter lesions in multiple sclerosis patients. *Neural Regeneration Research*, **2017**, 12, 787-794	4.5	11
48	The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. *BMC Medical Imaging*, **2016**, 16, 56	2.9	11
47	Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. *PLoS ONE*, **2018**, 13, e0206939	3.7	11
46	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. *International Journal of Neuroscience*, **2017**, 127, 971-980	2	10
45	The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. *Journal of the Neurological Sciences*, **2019**, 403, 38-43	3.2	10

44	7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. *Brain*, **2020**, 143, 2973-2987	11.2	10
43	Effects of Systolic Blood Pressure on Brain Integrity in Multiple Sclerosis. *Frontiers in Neurology*, **2018**, 9, 487	4.1	9
42	Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. *ENeurologicalSci*, **2018**, 12, 42-46	2.1	9
41	A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. *International Journal of Neuroscience*, **2017**, 127, 396-403	2	8
40	Diffusion-Weighted Magnetic Resonance Imaging in Superior Sagittal Sinus Thrombosis. *Journal of Neuroimaging*, **2002**, 12, 267-270	2.8	8
39	Aggressive giant pituitary adenoma presenting as a nasopharyngeal mass: magnetic resonance imaging and pathologic findings. *Journal of Neuro-Oncology*, **1999**, 41, 71-5	4.8	8
38	The NAIMS cooperative pilot project: Design, implementation and future directions. *Multiple Sclerosis Journal*, **2018**, 24, 1770-1772	5	8
37	An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis. *Journal of Neurology*, **2016**, 263, 531-8	5.5	7
36	Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. *Journal of the Neurological Sciences*, **2018**, 392, 94-99	3.2	7
35	Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. *Journal of the Neurological Sciences*, **2011**, 303, 109-13	3.2	7
34	TSPO-PET Imaging to Assess Cerebral Microglial Activation in Multiple Sclerosis. *Seminars in Neurology*, **2017**, 37, 546-557	3.2	7
33	Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. *NeuroImage*, **2015**, 119, 81-8	7.9	6
32	Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. *Npj Digital Medicine*, **2020**, 3, 135	15.7	6
31	Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis. *International Journal of MS Care*, **2017**, 19, 158-164	2.3	5
30	TAPAS: A Thresholding Approach for Probability Map Automatic Segmentation in Multiple Sclerosis. *NeuroImage: Clinical*, **2020**, 27, 102256	5.3	4
29	Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. *Journal of Neuroimaging*, **2020**, 30, 212-218	2.8	4
28	Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis. *Brain and Behavior*, **2018**, 8, e01068	3.4	4
27	Optimized double inversion recovery for reduction of T□weighting in fluid-attenuated inversion recovery. *Magnetic Resonance in Medicine*, **2012**, 67, 81-8	4.4	4

26	MRI activity in MS and completed pregnancy: Data from a tertiary academic center. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	4
25	The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. *Frontiers in Neurology*, **2016**, 7, 99	4.1	4
24	Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 593-602	5	4
23	Serum antibodies to phosphatidylcholine in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	3
22	Regional microglial activation in the substantia nigra is linked with fatigue in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	3
21	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. *Journal of Neuroimaging*, **2021**, 31, 388-393	2.8	3
20	Microstructural Changes in the Left Mesocorticolimbic Pathway are Associated with the Comorbid Development of Fatigue and Depression in Multiple Sclerosis. *Journal of Neuroimaging*, **2021**, 31, 501-507	2.8	3
19	A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	3
18	Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease. *Therapeutic Advances in Neurological Disorders*, **2016**, 9, 105-17	6.6	2
17	Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis. *Journal of the Neurological Sciences*, **2009**, 278, 54-9	3.2	2
16	Detection of Cortical and Deep Gray Matter Lesions in Multiple Sclerosis Using DIR and FLAIR at 3T. *Journal of Neuroimaging*, **2021**, 31, 408-414	2.8	2
15	Robust Multiple Sclerosis Lesion Inpainting with Edge Prior.. *Lecture Notes in Computer Science*, **2020**, 12436, 120-129	0.9	2
14	A dual modeling approach to automatic segmentation of cerebral T2 hyperintensities and T1 black holes in multiple sclerosis. *NeuroImage: Clinical*, **2018**, 20, 1211-1221	5.3	2
13	MIMoSA: An Approach to Automatically Segment T2 Hyperintense and T1 Hypointense Lesions in Multiple Sclerosis. *Lecture Notes in Computer Science*, **2019**, 47-56	0.9	1
12	Atrophy of the Brain and Spinal Cord in Multiple Sclerosis. *Journal of Neuroimaging*, **2004**, 14, 3S-4S	2.8	1
11	Detection of Metals in Multiple Sclerosis Brain Tissue using Scanning Electron Microscopy (SEM) and Energy Dispersive X-ray (EDX) Analyses. *Microscopy and Microanalysis*, **2004**, 10, 1342-1343	0.5	1
10	Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS.. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2022**, 8, 20552173211069348	2	1
9	Neuroimaging Curriculum for Neurology Trainees: Report from the Neuroimaging Section of the AAN **2003**, 13, 215		1

8	Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 20552173211015503	2	1
7	Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.. *Multiple Sclerosis Journal*, **2022**, 13524585221092309	5	0
6	Update in neuroimaging. *Neurotherapeutics*, **2011**, 8, 2	6.4	
5	Magnetic Resonance Imaging in Multiple Sclerosis **2012**, 136-162		
4	Neuroimaging essentials for the clinician. *Seminars in Neurology*, **2008**, 28, 393-4	3.2	
3	Imaging of multiple sclerosis: Role in neurotherapeutics. *Neurotherapeutics*, **2005**, 2, 277-303	6.4	
2	A local group differences test for subject-level multivariate density neuroimaging outcomes. *Biostatistics*, **2021**, 22, 646-661	3.7	
1	Exacerbation of Multiple Sclerosis by BRAF/MEK Treatment for Malignant Melanoma: The Central Vein Sign to Distinguish Demyelinating Lesions From Metastases. *Journal of Investigative Medicine High Impact Case Reports*, **2021**, 9, 23247096211033047	1.2	